Effect of Implantation and Fixation of Mirena in the Treatment of Adenomyosis and its Influence on Serum Inflammatory Factors

article OA: hybrid CC0 ⤵ 1 in-corpus citation
AI-generated summary by claude@2026-06, 2026-06-08

Intraoperative Mirena placement in adenomyosis patients reduced uterine volume, pain, inflammatory markers, and recurrence while improving quality of life compared to triptorelin treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text

This paper evaluated the effect of Mirena implantation and fixation during surgery on outcomes in 100 hospitalized adenomyosis patients enrolled from June 2019 to June 2021, comparing lottery-assigned groups receiving either intraoperative Mirena (n=50) or postoperative intramuscular triptorelin (n=50). Outcomes included sex hormone indices, VAS dysmenorrhea scores, uterine volume, serum inflammatory factors (IL-8 and TNF-α), adverse reaction incidence, WHOQOL-BREF quality-of-life scores, and recurrence rate. The Mirena group showed lower post-treatment VAS and uterine volume, lower serum IL-8 and TNF-α, higher WHOQOL-BREF scores, and a lower recurrence rate (0 vs 12.00%), with fewer total adverse reactions (4.00% vs 8.00%); the authors report no obvious adverse reactions. This paper is centrally about adenomyosis—Mirena implantation and fixation and its influence on serum inflammatory factors and clinical outcomes.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

This experiment was carried out to analyze the placement and fixation of Mirena in the treatment of adenomyosis (AM) and its influence on the level of serum inflammatory factors in patients. For this purpose, the subjects of this study were 100 AM patients hospitalized in our hospital from June 2019 to June 2021. They were divided into two groups according to the lottery method (n=50 for each group). The control group was treated with intramuscular triptorelin after the operation, and the observation group was treated with Mirena during the operation. Sex hormone indexes, VAS score, uterine volume, serum inflammatory indexes, the total incidence of adverse reactions, WHOQOL-BREF score and recurrence rate were compared between the two groups. Results showed that in the observation group after treatment E2VAS score and uterine volume were lower, serum IL-8 and TNF-A were lower, the whoqOL-BREf score was higher, and the recurrence rate (0) was lower than that in the control group (12.00%). The total incidence of adr in the observation group (4.00%) was lower than in the control group (8.00%). Then intraoperative placement of Mirena can effectively regulate sex hormone indexes of AM patients, reduce uterine volume, relieve dysmenorrhea symptoms, reduce the inflammatory response, improve quality of life, and reduce recurrence rate, without obvious adverse reactions.
Full text 2,649 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

This experiment was carried out to analyze the placement and fixation of Mirena in the treatment of adenomyosis (AM) and its influence on the level of serum inflammatory factors in patients. For this purpose, the subjects of this study were 100 AM patients hospitalized in our hospital from June 2019 to June 2021. They were divided into two groups according to the lottery method (n=50 for each group). The control group was treated with intramuscular triptorelin after the operation, and the observation group was treated with Mirena during the operation. Sex hormone indexes, VAS score, uterine volume, serum inflammatory indexes, the total incidence of adverse reactions, WHOQOL-BREF score and recurrence rate were compared between the two groups. Results showed that in the observation group after treatment E2VAS score and uterine volume were lower, serum IL-8 and TNF-A were lower, the whoqOL-BREf score was higher, and the recurrence rate (0) was lower than that in the control group (12.00%). The total incidence of adr in the observation group (4.00%) was lower than in the control group (8.00%). Then intraoperative placement of Mirena can effectively regulate sex hormone indexes of AM patients, reduce uterine volume, relieve dysmenorrhea symptoms, reduce the inflammatory response, improve quality of life, and reduce recurrence rate, without obvious adverse reactions.

Keywords

Download Citation Endnote/Zotero/Mendeley (RIS)BibTeX

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Outcome instruments

VAS-pain

Condition tags

dysmenorrheaadenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Levonorgestrel Levonorgestrel

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-16T06:07:01.518242+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-06-16T06:06:28.507379+00:00
License: CC0 · commercial use OK